Chemomab Therapeutics Ltd.
CMMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | -0.01 | 0.07 |
| FCF Yield | -47.35% | -394.06% | -56.13% | -17.62% |
| EV / EBITDA | -1.92 | 0.11 | -0.81 | -4.64 |
| Quality | ||||
| ROIC | -105.46% | -145.77% | -76.82% | -19.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.11 | 0.97 | 0.74 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 34.84% | -15.54% | -62.04% | -138.88% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.35 | 0.47 | 1.16 |
| Interest Coverage | 0.00 | 0.00 | -80.83 | -111.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.03 |
| Cash Conversion Cycle | -4,564.98 | -2,818.32 | -10,664.50 | -28,794.25 |